Activity monitoring biomarker

Capturing daily activities of ambulant and non-ambulant boys

The DRF has awarded £320,000 to Dr Aldo Faisal’s team at Imperial College London to develop and test activity monitoring devices. This entails using sensors worn by both ambulant and non-ambulant Duchenne patients to monitor their daily activities.

One of the major challenges in Duchenne drug development is linking measureable clinical trial endpoints with actual quality of life benefits. While there is a measurable and predictable decline in function during the course of the disease, each boy declines in a unique way, which can be hard to measure through classic functional tests like the six-minute walk test. This vital research aims to complement or even replace classic clinical endpoints, more sensitively capturing functional changes, and increasing the number of boys and young men eligible for clinical trials. The study of this new technology will be carried out as a clinical natural history study at the Clinical Research Facility of Great Ormond Street Hospital Trust, overseen by Professor Thomas Voit.

Biomarker research

£320,000 committed

Funded in 2017-18

London, UK

Learn more about this ground-breaking technology

The development and approval of disease-modifying treatments is often slowed down by the fact that it takes a long time to determine if a treatment works well or not for a group of patients. Many gold-standard methods for tracking disease progression rely on judgements ‘by eye’ in the clinic. This is especially true in ‘slow’ degenerative disorders such as Duchenne. We have now the unique opportunity to translate our artificial intelligence technology to the monitoring of Duchenne progression. We will give Duchenne boys wearable sensors, which will capture their arm and leg movement where it matters most to them: at home and in school. This movement data is collected discreetly, 24/7, and will be analysed by our artificial intelligence technology. This is a bit like having a personal neurologist looking after you day and night, day after day, who can notice even subtle changes in movement ability. We hope that these novel approaches will significantly improve the accuracy and reduce the time it takes to detect disease progression, potentially reducing the duration of future clinical trials and the cost of treatment development. We are delighted to have a forward looking clinical partner in Great Ormond Street’s Clinical Research Facility, with whom we will be working closely.

Click here to learn more about Dr Faisal’s work

Dr Aldo Faisal

Associate Professor in Neurotechnology jointly at the Department of Bioengineering and the Department of Computing at Imperial College London

Why are we supporting this project?

Despite the significant acceleration of therapeutic developments in the field of Duchenne in the last few years, a number of issues remain to be solved and require dedicated support and attention. We need better and more reliable outcome measures for boys with Duchenne, which is an area that has been insufficiently explored in the field so far. Characterisation of better outcome measures will enable the field to monitor disease progression and benefits of any therapeutic strategies in a more coherent and reliable manner. The newly funded projects supported by the Duchenne Research Fund will address those shortcomings and I am confident that the successful completion of those will make seminal contributions to the field of Duchenne.

Professor Ronald Cohn

Head of the DRF Scientific Advisory Board; Chair, Department of Paediatrics, University of Toronto; Paediatrician-in-Chief, The Hospital for Sick Children, Toronto

Our projects

View our other newly funded research projects.

Get involved

Find out how you can help us beat Duchenne.